| Apr-2022 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA. | John, Thomas ; Sakai, Hiroshi; Ikeda, Satoshi; Cheng, Ying; Kasahara, Kazuo; Sato, Yuki; Nakahara, Yoshiro; Takeda, Masayuki; Kaneda, Hiroyasu; Zhang, Helong; Maemondo, Makoto; Minato, Koichi; Hisada, Takeshi; Misumi, Yuki; Satouchi, Miyako; Hotta, Katsuyuki; Li, Ang; Oukessou, Abderrahim; Lu, Shun |
| Feb-2021 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. | Paz-Ares, Luis; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Schenker, Michael; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Felip, Enriqueta; Juan-Vidal, Oscar; Alexandru, Aurelia; Sakai, Hiroshi; Lingua, Alejo; Salman, Pamela; Souquet, Pierre-Jean; De Marchi, Pedro; Martin, Claudio; PĂ©rol, Maurice; Scherpereel, Arnaud; Lu, Shun; John, Thomas ; Carbone, David P; Meadows-Shropshire, Stephanie; Agrawal, Shruti; Oukessou, Abderrahim; Yan, Jinchun; Reck, Martin |